Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

EpiPen Outrage In Congress Puts Spotlight On FDA Generic Review

Aug 30 2016

• By Derrick Gingery

Capitol House

Related Content

Cheap Drugs Create Quality Temptations, FDA Official Says

Dec 04 2015

<em>Copaxone</em> Generics: FDA Approval Standards Defy Teva’s Argument On Complexity

Apr 27 2015

Drug Pricing Panacea Or Just PR Victory? Expedited ANDAs May Have Limited Impact

Mar 21 2016

FDA's Combo Products Review Transformation Begins

Aug 24 2016

PDUFA First: Fees To Support Device Center Staff

Aug 24 2016

FDA To Update Quality Metrics Guidance

Aug 09 2016

Mylan’s EpiPen Exclusivity Saved Again As Teva Reports CRL

Mar 01 2016

Why Generic EpiPen Is Not The Answer – Until FDA Says It Is

Aug 29 2016

Mylan's Generic EpiPen: A Good PR Move, But Risks Alienating Payers

Aug 29 2016

Related Companies

Viatris Inc.

Teva Pharmaceutical Industries Ltd.

Sanofi

Additional Topics

United States Legislation Review Pathway Drug Review Regulation Pricing Debate Combination Products BioPharmaceutical

More from Legislation

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window